Therefore, we examined the clinical characteristics of patients who were administered Humalog U-200 insulin in routine clinical practice and to describe using questionnaires, patients’ perceptions of their diabetes treatment following the use of Humalog U-200 KwikPen, compared with their previous mealtime insulin pen (PMIP) of >3 months duration. The gene discussed is INS; the disease is diabetes mellitus.